3.34
0.13 (4.02%)
| Previous Close | 3.21 |
| Open | 3.34 |
| Volume | 19,807 |
| Avg. Volume (3M) | 22,243 |
| Market Cap | 27,856,318 |
| Price / Sales | 3.15 |
| Price / Book | 8.66 |
| 52 Weeks Range |
| Operating Margin (TTM) | -431.34% |
| Diluted EPS (TTM) | -12.00 |
| Quarterly Revenue Growth (YOY) | 67.10% |
| Total Debt/Equity (MRQ) | 837.11% |
| Current Ratio (MRQ) | 2.01 |
| Operating Cash Flow (TTM) | -12.94 M |
| Levered Free Cash Flow (TTM) | -11.59 M |
| Return on Assets (TTM) | -37.07% |
| Return on Equity (TTM) | -206.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Evaxion A/S | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.83 |
|
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 23.07% |
| % Held by Institutions | 7.09% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Merck & Co., Inc. | 30 Jun 2026 | 1,214,126 |
| Annis Gardner Whiting Capital Advisors, Llc | 30 Jun 2026 | 30,000 |
| J. Safra Sarasin Holding Ag | 30 Jun 2026 | 22,896 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |